- Home
- STTK vs LSB Comparison
STTK vs LSB Comparison
Compare STTK & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- LSB
- Stock Information
- Founded
- STTK 2016
- LSB 2002
- Country
- STTK United States
- LSB China
- Employees
- STTK N/A
- LSB N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- LSB
- Sector
- STTK Health Care
- LSB
- Exchange
- STTK Nasdaq
- LSB NYSE
- Market Cap
- STTK 36.2M
- LSB 31.5M
- IPO Year
- STTK 2020
- LSB N/A
- Fundamental
- Price
- STTK $0.84
- LSB $1.39
- Analyst Decision
- STTK Hold
- LSB
- Analyst Count
- STTK 4
- LSB 0
- Target Price
- STTK $3.00
- LSB N/A
- AVG Volume (30 Days)
- STTK 305.5K
- LSB 26.5K
- Earning Date
- STTK 05-01-2025
- LSB 06-21-2025
- Dividend Yield
- STTK N/A
- LSB N/A
- EPS Growth
- STTK N/A
- LSB N/A
- EPS
- STTK N/A
- LSB N/A
- Revenue
- STTK $5,721,000.00
- LSB $79,415,311.00
- Revenue This Year
- STTK N/A
- LSB $39.33
- Revenue Next Year
- STTK N/A
- LSB $75.61
- P/E Ratio
- STTK N/A
- LSB N/A
- Revenue Growth
- STTK 245.26
- LSB N/A
- 52 Week Low
- STTK $0.69
- LSB $1.26
- 52 Week High
- STTK $11.76
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- STTK 44.82
- LSB 30.77
- Support Level
- STTK $0.73
- LSB $1.26
- Resistance Level
- STTK $0.90
- LSB $1.79
- Average True Range (ATR)
- STTK 0.15
- LSB 0.22
- MACD
- STTK 0.00
- LSB -0.06
- Stochastic Oscillator
- STTK 19.96
- LSB 6.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.